Grifols stock forecast: Third-party price targets
Grifols is a Spanish healthcare company specialising in plasma-derived medicines, listed in Madrid and the US, with its shares traded by investors following developments in earnings, debt and regulation. Explore third-party GRLS price targets and technical analysis.
Grifols, S.A. (GRLS) is trading around €10.86 in late European hours on 23 January 2026, holding near the top of its intraday range between €10.63 and €10.90, according to Capital.com pricing at 9:49am UTC. Past performance is not a reliable indicator of future results.
Recent price action comes amid Grifols’ plan to rely more on public debt markets for future refinancing (Bloomberg, 28 February 2025). Separately, a board decision effective 1 January 2026 reshuffled the secretary and vice-secretary non-member roles, following a recommendation from the Appointments and Remuneration Committee (Stock Titan, 8 January 2026).
Grifols stock forecast 2026–2030: Third-party price targets
As of 23 January 2026, third-party Grifols stock predictions reflect a range of views on the company’s deleveraging path, earnings recovery and sector risk appetite as of late 2025 and early 2026. Most published forecasts are framed over a 12-month horizon for the Madrid-listed and US-listed shares. These figures represent indicative opinions from third-party institutions, not guarantees, and may be revised as new information emerges.
JP Morgan (broker research)
JP Morgan maintains a neutral stance on Grifols, with a reduced 12-month price target of $10 for the US-listed line as of, down from $10.30 previously, according to a note summarised by GuruFocus. The broker cites an ongoing reassessment of leverage and cash generation as the group works through refinancing and operational plans (GuruFocus, 8 December 2025).
MarketBeat (consensus screen)
MarketBeat reports that, based on the most recent updates from five Wall Street analysts over the past year, the average 12-month target for Grifols’ US-listed shares stands around $10. The service notes a 'Moderate Buy' consensus, with analysts pointing to potential upside if cost-saving and balance-sheet measures progress broadly in line with internal plans (MarketBeat, 23 January 2026).
Public.com (aggregated view)
Public.com indicates that as of January 2026, analysts contributing to its platform have set a central price target of about $10 for Grifols’ US line, suggesting limited projected movement relative to the then-prevailing market price. Commentary links this flat profile to mixed sentiment around the pace of deleveraging and ongoing sector volatility following earlier share-price swings (Public.com, 19 January 2026).
Zacks Investment Research (broker screen)
Zacks reports that the average short-term price target for Grifols’ US-listed shares was $12.15, with individual estimates ranging from $10.30 to $14. The spread reflects differing assumptions around leverage reduction and earnings recovery within analyst models (Zacks Investment Research, 10 January 2025).
Investing.com (consensus estimates)
Investing.com shows that, based on projections from 12 analysts, the average 12-month target for Grifols’ Madrid-listed shares stood near €15.06, with estimates ranging from €9 to €22.20. The platform cites a Buy-tilted recommendation structure, linked to expectations for revenue growth and margin improvement, while acknowledging a wide dispersion of views (Investing.com, 23 January 2026).
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
GRLS stock price: Technical overview
The GRLS stock price is trading near €10.86 as of 9:49am UTC on 23 January 2026, with price hovering just above the 10-day SMA around €10.90 and within a broader cluster of the 20-, 50-, 100- and 200-day SMAs, located near approximately €11.0, €10.8, €11.3 and €10.9 respectively. Short-term EMAs sit in a similar range, with the 10-day EMA near €10.87 and the 200-day EMA around €10.89, suggesting a relatively flat medium-term profile. RSI(14) is around 48, indicating neutral momentum, while ADX(14) near 14.9 points to a weak trend environment rather than a sustained directional move.
On the upside, initial resistance is located near €11.11 (R1), with a daily close above that level bringing the €11.51 region (R2) into focus. On pullbacks, initial support sits near the €10.73 pivot, while the 200-day SMA around €10.94 may act as a nearby dynamic reference point. A sustained move below the €10.33–€10.32 S1 area could expose the €9.95 zone (S2) within the same framework (TradingView, 23 January 2026).
This technical analysis is provided for informational purposes only and does not constitute financial advice or a recommendation to trade.
Grifols share price history (2024–2026)
GRLS’s stock price has experienced a pronounced round-trip over the past two years, moving from single-digit levels to the low teens and back again. The stock closed at €9.45 on 25 January 2024 before sliding to around €7.20 in mid-March. It then rebounded to end 2024 at €9.20 on 31 December. By late October 2025, Grifols was trading near recent highs around €12.67–€13.21, before easing into year-end and declining from roughly €11.21 at the start of 2026 to €10.86 by the close on 23 January 2026.
Past performance is not a reliable indicator of future results.
Grifols (GRLS): Capital.com analyst view
Grifols’ share price over the past two years reflects a balance between improving operational performance and ongoing balance-sheet considerations. The stock moved from below €8 in early 2024 to trade in the low-to-mid teens during parts of 2025, before easing back toward the €10–€11 area by January 2026. This pattern coincided with stronger reported earnings alongside continued scrutiny of leverage and refinancing plans. As a result, GRLS has remained relatively volatile compared with some broader healthcare peers, with price movements often aligned with updates on cash flow, margins and debt reduction.
On the supportive side, Grifols has reported record revenue and higher profitability, while rating agencies and lenders have acknowledged progress in reducing leverage and strengthening liquidity as the group executes its value-creation plan and refinances near-term maturities. At the same time, the capital structure remains a key risk factor. Elevated leverage, sensitivity to refinancing costs, and sector-wide regulatory or pricing developments mean that the same macroeconomic or company-specific news can reinforce optimism for some market participants while prompting caution for others, particularly if execution or market conditions fall short of expectations.
Summary – Grifols 2026
- Grifols (GRLS) is quoted around €10.86 as of 9:49am UTC on 23 January 2026, near the upper end of its intraday range between €10.63 and €10.90.
- Over the past two years, the share price has ranged from below €8 in early 2024 to highs above €13 in mid-2025, before moderating toward the €10–€11 area in early 2026.
- Technical indicators show GRLS trading just below a dense 20-, 50-, 100- and 200-day moving-average band between roughly €10.8 and €11.3, with RSI(14) near neutral levels and ADX pointing to a weak trend environment.
- Company disclosures highlight higher revenues and improved profitability through 2024–2025, alongside active efforts to refinance 2025–2026 debt maturities and reduce leverage.
- External commentary points to potential support from improving cash generation and exposure to plasma-derived therapies, while key risks continue to centre on leverage levels, refinancing costs and sector-specific regulatory or pricing uncertainty.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Grifols stock?
Grifols has a mixed shareholder base that includes founding family interests, institutional investors and public shareholders. The Grifols family continues to exert significant influence through ownership stakes and governance roles, while large asset managers and funds hold positions via the company’s Madrid-listed shares and US-listed ADRs. Ownership levels can change over time as institutions adjust exposure, meaning reported holdings represent a point-in-time view rather than a fixed structure.
What is the five-year Grifols share price forecast?
There is no single, reliable five-year share price forecast for Grifols. Most publicly available analyst estimates focus on a 12-month horizon and vary widely depending on assumptions around leverage reduction, cash flow generation and operational execution. Longer-term valuation approaches, including discounted cash flow models, are highly sensitive to their inputs and are best viewed as illustrative scenarios rather than forecasts of future performance.
Is Grifols a good stock to buy?
Whether Grifols is considered a 'good' stock depends on individual objectives, risk tolerance and time horizon. Some analysts point to improving profitability and efforts to strengthen the balance sheet, while others remain cautious due to elevated leverage and refinancing exposure. As with any listed company, potential upside is accompanied by material risks, and published views reflect differing analytical assumptions rather than a single agreed outlook.
Could Grifols stock go up or down?
Yes. Grifols’ share price can move higher or lower in response to company-specific developments, broader market conditions and sector trends. Earnings results, progress on debt reduction, refinancing costs and regulatory changes may all influence price movements. Market sentiment and liquidity conditions can also contribute to volatility, meaning outcomes may differ from analyst expectations at any given time.
Should I invest in Grifols stock?
This article does not provide investment advice or recommendations. Decisions about investing in Grifols should be based on your own research, financial situation and understanding of the risks involved. Share prices can rise or fall, and losses as well as gains are possible, while past performance is not a reliable indicator of future results. If appropriate, consider seeking guidance from an independent financial adviser before making any investment decision.
Can I trade Grifols CFDs on Capital.com?
Yes, you can trade Grifols CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.